Search
for
Sort by
Research 30 of 1000+
- Co-Relation Between Androgenetic Alopecia and Severity of COVID-19 Disease – A Cross-Sectional Study
- Efficacy and safety of microneedling and oral tranexamic acid in the treatment of facial melasma in women: An open, evaluator-blinded, randomized clinical trial
- Exploring Clinical and Imaging Differences in COVID-19: an Observational Approach to the IFITM3 rs12252 Polymorphism
- Evaluation of SALT score severity in correlation with trichoscopic findings in alopecia areata: a study of 303 patients
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Objective outcome measures: Collecting meaningful data on alopecia areata
- PD-1+CXCR5−CD4+T cells are correlated with the severity of systemic lupus erythematosus
- Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
- Free Testosterone Levels in Patients with Covid-19 and its Association with Disease Severity
- When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
- Bempikibart shows its potential for hair regrowth in alopecia areata
- Not just thinning: A case of alopecia universalis after mild COVID-19
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Dietary Habits in Japanese Patients with Alopecia Areata
- Cross sectional quality of life assessment in patients with androgenetic alopecia
- The Predictive Value of Clinical Hirsutism for Biochemical Hyperandrogenism in a Large Endocrine Referral Cohort
- Relationships between cerebrospinal fluid GABAergic neurosteroid levels and symptom severity in men with PTSD
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- Hearing impairment in patients with alopecia areata
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Narrowband UVB treatment induces expression of WNT7B, WNT10B and TCF7L2 in psoriasis skin
- An Open-Label Comparative Study on the Effects of Platelet-Rich Plasma Therapy with Hydroquinone 4% Versus Hydroquinone 4% Alone in Melasma
- The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)